Allspring Global Investments Holdings LLC Sells 2,996 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Allspring Global Investments Holdings LLC trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 12.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,709 shares of the specialty pharmaceutical company’s stock after selling 2,996 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Supernus Pharmaceuticals were worth $754,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SUPN. Polaris Capital Management LLC raised its position in Supernus Pharmaceuticals by 10.6% in the fourth quarter. Polaris Capital Management LLC now owns 47,000 shares of the specialty pharmaceutical company’s stock worth $1,700,000 after acquiring an additional 4,500 shares during the period. Newbridge Financial Services Group Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $72,000. Empowered Funds LLC purchased a new stake in Supernus Pharmaceuticals in the fourth quarter worth about $1,498,000. Meritage Portfolio Management raised its stake in shares of Supernus Pharmaceuticals by 8.8% in the fourth quarter. Meritage Portfolio Management now owns 48,181 shares of the specialty pharmaceutical company’s stock worth $1,742,000 after buying an additional 3,886 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Supernus Pharmaceuticals by 87.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 19,866 shares of the specialty pharmaceutical company’s stock valued at $718,000 after buying an additional 9,267 shares in the last quarter.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald cut shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $57.00 to $36.00 in a research note on Wednesday, February 19th.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $33.05 on Monday. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of 30.89 and a beta of 0.90. The company has a 50-day moving average of $37.48 and a 200 day moving average of $35.38. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28.

Insider Buying and Selling

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. This represents a 48.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 9.30% of the stock is owned by insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.